The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
This is an exciting and meaningful milestone for GRIN Therapeutics
The Danish biotech company confirmed the global study will begin in the second half of 2026
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
New formulation by Greenspace Herbs to target improved efficacy and lower dosage in curcumin supplements
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
Subscribe To Our Newsletter & Stay Updated
